Project Grant R50CA318775
Award Date 8/11/26
Completion Date 7/31/31
Dollars Obligated $129K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23298, USA
Similar Awards
- The National Cancer Institute awarded the University of Virginia $514,563 under the Cancer Treatment Research program (CFDA 93.395) on September 1, 2026, to develop adaptive randomization designs for identifying optimal dose combinations in early-phase clinical trials applicable to both oncology and non-oncology agents. The project targets the practical implementation of FDA Project Optimus principles by creating flexible early-stage trial designs that balance treating study participants with...
- The National Cancer Institute awarded Virginia Commonwealth University $634,062 on June 5, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate atypical sphingolipids in hepatocellular carcinoma (HCC) metabolism and identify SPTLC3 as a potential therapeutic target. The award funds three research aims examining how the SPTLC3 enzyme subunit regulates metabolic pathways in liver cancer cells. Aim 1 determines the scope of SPTLC3-mediated metabolic regulation in...
- The National Cancer Institute awarded Virginia Commonwealth University $511,930 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to identify molecular determinants of response and resistance to TROP2-targeted antibody-drug conjugates and develop strategies to enhance therapeutic efficacy in triple-negative breast cancer and pancreatic adenocarcinoma. The project spans five years through July 31, 2031, with work performed in Richmond, Virginia. The research...
- The National Cancer Institute awarded Virginia Commonwealth University $399,187 under the Cancer Treatment Research program (CFDA 93.395) on May 7, 2026, to develop glycosaminoglycans-based theragnostic approaches for treating platinum-resistant gynecological malignancies, specifically ovarian cancer. The project supports exploratory and developmental research on how sulfated glycosaminoglycans, including heparan sulfate and chondroitin sulfate, mediate tumor uptake of platinum-based...
- The National Cancer Institute awarded $269,597 to the Beckman Research Institute of The City of Hope on August 10, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop and deliver clinical trials nursing education. The recipient will create a curriculum to train oncology clinical trials nurses in quality care for patients enrolled in cancer treatment trials, deliver the curriculum through five national in-person courses and virtual offerings to competitively selected...
- The National Cancer Institute awarded $194,909 to the University of Florida on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop and deliver the T-CAT (Trainees Communicating About Trials) Program, which trains physician trainees to communicate with patients about cancer clinical trials across the cancer continuum. The program addresses documented barriers to cancer clinical trial accrual, which remains at approximately 7–8 percent of cancer patients, with...
- The National Cancer Institute awarded the University of Virginia $192,887 on May 8, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research on sphingolipid-guided stratification and therapeutic opportunities in acute myeloid leukemia. The project investigates sphingolipid metabolism as a mechanism to improve acute myeloid leukemia risk classification beyond genomic characterization. Prior work identified two AML patient subtypes distinguished by reciprocal abundance of...
- The National Cancer Institute awarded Virginia Commonwealth University $203,148 on August 21, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop and test the Colon Health Champion Program, a peer-led intervention designed to increase colorectal cancer screening rates among low-income residents of HUD-administered housing in Virginia. The project will develop and pilot a community-engaged intervention using the ORBIT model for intervention development, then conduct a...
- This Project Grant award for $399,187 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support Virginia Commonwealth University's research to develop novel genetically engineered mouse models to study the development of marginal zone lymphomas (MZL). The research aims to 1) investigate the impact of activation of the PI3K/AKT/mTOR pathway on MZL development, and 2) determine optimal drug combinations for targeting this pathway in MZL. This work seeks to establish...
- The National Cancer Institute awarded $415,257 to the University of Virginia on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop a comprehensive intervention addressing financial toxicity among cancer survivors and caregivers. The award funds a two-year project (July 1, 2026 through June 30, 2028) performed in Charlottesville, Virginia. The intervention will address all domains of financial toxicity—material burden, psychosocial distress, and coping...